 | | Vol. 12.01 – 12 January, 2021 |
| |
|
|
| Scientists report that UM171 potentiated the activity of a CULLIN3-E3 ubiquitin ligase complex whose target specificity was dictated by the poorly characterized Kelch/BTB domain protein KBTBD4.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers detected an increase in the number of both young and aged mouse bone marrow (BM) HSCs collected and processed in 3% O2 compared with the number of young BM HSCs collected and processed in ambient air.
[Journal of Clinical Investigation] |
|
|
|
| Using a novel conditional U2af1 knockout allele, investigators found that deletion of U2af1 results in profound defects in hematopoiesis characterized by pancytopenia, ablation of hematopoietic stem/progenitor cells leading to bone marrow failure and early lethality in mice.
[Leukemia] |
|
|
|
| Researchers studied the role of the outer mitochondrial membrane protein VDAC1 in human terminal erythropoiesis. They showed that shRNA-mediated downregulation of VDAC1 accelerated erythroblast maturation.
[Haematologica] |
|
|
|
| Scientists analyzed ~200,000 single-cell transcriptomes of bone marrow mononuclear cells and its subsets from 23 clinical samples. They constructed a comprehensive cell atlas as hematopoietic reference.
[Cell Discovery] |
|
|
|
| Investigators showed that protein synthesis rates declined during HSC ontogeny, yet erythroid protein synthesis rates increased. A ribosomal mutation that impairs ribosome biogenesis disrupted both fetal and adult HSC self-renewal.
[Stem Cell Reports] |
|
|
|
| As acute myeloid leukemia (AML) primary blasts express different levels of accessory protein of the interleukin-1 receptor (IL-1RAP), scientists modeled transduction of different AML tumor cell lines screened for density of antigenic sites with their lentiviral vectors carrying a third-generation IL-1RAP chimeric antigen receptor, an iCASP9 suicide gene, and a truncated CD19 surface gene.
[Cancer Gene Therapy] |
|
|
|
| The authors conducted two lines of genome-editing experiments of mouse HSCs with the clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein 9 (Cas9).
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Scientists found that Zinc finger protein 521 (Zfp521) deletion did not inhibit adult hematopoiesis under homeostatic conditions. In contrast, Zfp521-null chimeric mice showed significantly reduced pool size of HSCs and hematopoietic progenitor cells associated with increased apoptosis and loss of quiescence.
[iScience] |
|
|
|
| The authors identified novel potential microRNAs bound up with the diagnosis and prognosis of myelodysplastic syndromes (MDS). miRNA microarray analysis was used to screen deregulated microRNAs in the bone marrow of MDS patients.
[Scientific Reports] |
|
|
|
| Researchers developed a mice model for studying the hematopoietic syndrome in the non-uniform or partial body exposure scenarios using the localized cobalt60 gamma radiation exposure.
[Scientific Reports] |
|
|
|
|
| The authors review several biological and clinical aspects related to leukemia-initiating cells (LICs) in acute lymphoblastic leukemia (ALL), including: 1) immunophenotypic characterization of LIC-enriched subsets in human and mouse models of ALL; 2) emerging therapeutics against regulatory signaling pathways involved in LIC progression and maintenance in T- and B-cell leukemias; 3) novel epigenetic and age-related mechanisms of LIC propagation, and 4) ongoing efforts in immunotherapy to eradicate LIC-enriched cell subsets in relapsed and refractory ALL cases.
[Cancer Research] |
|
|
|
|
| Apollomics, Inc., and GlycoMimetics announced APL-106 has been granted Breakthrough Therapy Designation from the China National Medical Products Administration Center for Drug Evaluation for the treatment of relapsed/refractory acute myeloid leukemia. Uproleselan is designed to block E-selectin from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment.
[Apollomics, Inc.] |
|
|
|
|
| March 14 – 17, 2021
Virtual |
|
|
|
|
|
| | STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
